Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 6/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197256 | 0.84 | ADRA1D (0.44) | CYP2A6CYP3A4CYP2C9CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL1017625 | 0.82 | ADRA1D (0.46) | CYP2A6CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL28167406 | 0.80 | RAB9A (0.42) | CYP3A4CYP2C9CYP2C19CYP1A2MAPK1 | |
| SCHEMBL4895563 | 0.80 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP1A2MAPK1 | |
| SCHEMBL24439885 | 0.79 | SLC6A4 (0.50) | CYP2A6CYP3A4CYP1A2LMNARAB9A | |
| SCHEMBL18685140 | 0.77 | ROCK2 (0.39) | CYP2A6CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2526394 | 0.76 | MPO (0.41) | IDO1PLA2G1BATG4BADRA1DADRA1A | |
| SCHEMBL1197126 | 0.74 | CYP3A4 (0.42) | CYP2A6CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL29070042 | 0.74 | KEAP1 (0.46) | CYP2C9ALDH1A1MAPT | |
| SCHEMBL701343 | 0.73 | CYP2A6 (0.48) | CYP2A6CYP3A4CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| CN-115572252-B | Isoindolinone inhibitors of MDM2-P53 interaction with anticancer activity | 阿斯泰克斯治疗有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2024-08-27 | — | — | US | disclosed |
| EP-4151633-A1 | INTERMEDIATES OF ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Limited (GB) | 2023-03-22 | — | — | EP | disclosed |
| CN-115572252-A | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2023-01-06 | — | — | CN | disclosed |
| EP-3356350-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2020-01-28 | — | — | US | disclosed |
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2020-01-28 | — | — | US | disclosed |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| EP-3356350-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Limited (GB) | 2018-08-08 | — | — | EP | disclosed |
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-1996545-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | Boehringer Ingelheim International GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | CYP2A6 2658/4885CYP3A4 1227/4885CYP2C9 2188/4885 |
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | CYP2A6 2658/4885CYP3A4 1227/4885CYP2C9 2188/4885 |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | CYP2A6 2566/4885CYP3A4 1087/4885CYP2C9 2099/4885 |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | CYP2A6 136/4885CYP3A4 155/4885CYP2C9 274/4885 |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | CYP2A6 376/4885CYP3A4 463/4885CYP2C9 477/4885 |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | CYP2A6 2658/4885CYP3A4 1227/4885CYP2C9 2188/4885 |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | CYP2A6 2658/4885CYP3A4 1227/4885CYP2C9 2188/4885 |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | CYP2A6 2658/4885CYP3A4 1227/4885CYP2C9 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.